From July 1 2018, the breast cancer medicine ribociclib (Kisqali®) was listed on the Pharmaceutical Benefits Scheme (PBS).
The new listing will benefit more than 3,000 Australian women with inoperable or metastatic hormone receptor positive breast cancer.
This medicine would otherwise cost each patient around $71,820 per year. Eligible patients will now pay $39.50 per script, or $6.40 with a concession card.
This $703.6 million Australian Government investment was made on the advice of the independent Pharmaceutical Benefits Advisory Committee (PBAC).
It’s another step toward ensuring all Australians can afford and access the medicines they need.
Learn more about the PBS.